文献速递心脑血管急症

替格瑞洛用于稳定性冠心病合并糖尿病患者

Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
PubMed 文献 · N Engl J Med · 2019-09-01
一句话结论稳定性冠心病合并2型糖尿病且无心肌梗死或卒中史患者,替格瑞洛联合阿司匹林较安慰剂联合阿司匹林降低缺血性心血管事件(7.7% vs 8.5%;HR 0.90),但增加TIMI大出血(2.2% vs 1.0%;HR 2.32)和颅内出血(0.7% vs 0.5%;HR 1.71)。

THEMIS随机双盲试验纳入19,220例50岁及以上稳定性冠心病合并2型糖尿病且无既往心肌梗死或卒中史患者,比较替格瑞洛联合阿司匹林与安慰剂联合阿司匹林的疗效与安全性。中位随访39.9个月,替格瑞洛组主要疗效终点(心血管死亡、心肌梗死或卒中)发生率为7.7%,低于安慰剂组的8.5%(HR 0.90;95%CI 0.81-0.99;P=0.04)。替格瑞洛组TIMI大出血发生率为2.2%,高于安慰剂组的1.0%(HR 2.32;95%CI 1.82-2.94;P<0.001),颅内出血发生率为0.7% vs 0.5%(HR 1.71;95%CI 1.18-2.48;P=0.005)。致死性出血发生率两组无显著差异(0.2% vs 0.1%;HR 1.90;95%CI 0.87-4.15;P=0.11)。不可逆伤害复合终点(全因死亡、心肌梗死、卒中、致死性出血或颅内出血)两组相似(10.1% vs 10.8%;HR 0.93;95%CI 0.86-1.02)。

要点

  • 稳定性冠心病合并2型糖尿病且无心肌梗死或卒中史患者,替格瑞洛联合阿司匹林较安慰剂联合阿司匹林降低缺血性心血管事件(7.7% vs 8.5%;HR 0.90;95%CI 0.81-0.99;P=0.04)。
  • 替格瑞洛联合阿司匹林增加TIMI大出血(2.2% vs 1.0%;HR 2.32;95%CI 1.82-2.94;P<0.001)和颅内出血(0.7% vs 0.5%;HR 1.71;95%CI 1.18-2.48;P=0.005)。
  • 致死性出血两组无显著差异(0.2% vs 0.1%;HR 1.90;95%CI 0.87-4.15;P=0.11)。
  • 不可逆伤害复合终点(全因死亡、心肌梗死、卒中、致死性出血或颅内出血)两组相似(10.1% vs 10.8%;HR 0.93;95%CI 0.86-1.02)。
  • 替格瑞洛组永久停药率高于安慰剂组(34.5% vs 25.4%)。

适用人群与场景

  • 年龄50岁及以上、稳定性冠心病合并2型糖尿病、无既往心肌梗死或卒中史的患者。
  • 排除既往有心肌梗死或卒中史的患者。

研究设计与关键结果

  • 随机双盲试验,共19,220例患者接受随机分组,中位随访39.9个月。
  • 主要疗效终点(心血管死亡、心肌梗死或卒中):替格瑞洛组7.7% vs 安慰剂组8.5%(HR 0.90;95%CI 0.81-0.99;P=0.04)。
  • 主要安全终点TIMI大出血:替格瑞洛组2.2% vs 安慰剂组1.0%(HR 2.32;95%CI 1.82-2.94;P<0.001)。
  • 颅内出血:替格瑞洛组0.7% vs 安慰剂组0.5%(HR 1.71;95%CI 1.18-2.48;P=0.005)。
  • 致死性出血:替格瑞洛组0.2% vs 安慰剂组0.1%(HR 1.90;95%CI 0.87-4.15;P=0.11),无显著差异。
  • 永久治疗终止:替格瑞洛组34.5% vs 安慰剂组25.4%。
  • 探索性不可逆伤害复合终点(全因死亡、心肌梗死、卒中、致死性出血或颅内出血):替格瑞洛组10.1% vs 安慰剂组10.8%(HR 0.93;95%CI 0.86-1.02)。

证据类型、等级与局限

  • 证据类型:随机双盲试验(THEMIS,ClinicalTrials.gov NCT01991795)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于稳定性冠心病合并2型糖尿病且无心肌梗死或卒中史的患者,替格瑞洛联合阿司匹林较安慰剂联合阿司匹林降低缺血性心血管事件,但增加TIMI大出血和颅内出血。
  • 致死性出血发生率两组无显著差异。
  • 不可逆伤害复合终点两组相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear.

METHODS: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin. Patients with previous myocardial infarction or stroke were excluded. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria.

RESULTS: A total of 19,220 patients underwent randomization. The median follow-up was 39.9 months. Permanent treatment discontinuation was more frequent with ticagrelor than placebo (34.5% vs. 25.4%). The incidence of ischemic cardiovascular events (the primary efficacy outcome) was lower in the ticagrelor group than in the placebo group (7.7% vs. 8.5%; hazard ratio, 0.90; 95% confidence interval [CI], 0.81 to 0.99; P = 0.04), whereas the incidence of TIMI major bleeding was higher (2.2% vs. 1.0%; hazard ratio, 2.32; 95% CI, 1.82 to 2.94; P<0.001), as was the incidence of intracranial hemorrhage (0.7% vs. 0.5%; hazard ratio, 1.71; 95% CI, 1.18 to 2.48; P = 0.005). There was no significant difference in the incidence of fatal bleeding (0.2% vs. 0.1%; hazard ratio, 1.90; 95% CI, 0.87 to 4.15; P = 0.11). The incidence of an exploratory composite outcome of irreversible harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was similar in the ticagrelor group and the placebo group (10.1% vs. 10.8%; hazard ratio, 0.93; 95% CI, 0.86 to 1.02).

CONCLUSIONS: In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. (Funded by AstraZeneca; THEMIS ClinicalTrials.gov number, NCT01991795.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019. PMID: 31475798. doi:10.1056/NEJMoa1908077

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。